Center for Cancer Immunology & Immunotherapy
Advancing cancer immunology & immunotherapy through pioneering research and a vibrant community of investigators.
Immunotherapy, Conquering Cancer
The UofL CCII is an NIH-supported program fostering a robust community of investigators and advanced biomedical research, driving impactful discoveries in cancer immunology and immunotherapy.
Featured Research & Projects
Overcoming Resistance to Cancer Immunotherapy by Targeting MDSC-derived Adenosine
Investigating how tumor-derived PGE2 drives CD73 expression on M-MDSCs, increasing adenosine and causing anti-PD-1 resistance in lung cancer.
Leveraging Zika virus-driven myeloid cell responses to treat GBM
Zika oncolytic virotherapy for glioblastoma (GBM) via targeting stem cells, reprograms tumor microenvironment to induce anti-tumor T-cell response.
The role of ECM-mediated mechanosignaling on regional immunosuppression in GBM
Investigates how ECM components & hyaluronic acid stiffness cause immunosuppression in GBM, by driving mesenchymal transition & M-MDSC infiltration.
Statistics
Over 90 peer-reviewed papers published and co-authored by our research project investigators.
15 Key Research and Pilot Research Projects supported.
Established Functional Immunomics Core Facility serving >40 researchers campus-wide.
Recent News
